Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1980 participants.
Also called NCT02226120
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,980 participants
- Sponsor
- Registry
-
NCT02226120 -
2014-001971-30
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Belgium, Brazil, Bulgaria, Canada, Chile, Czechia, Denmark, Estonia, Finland, France, Germany, Guatemala, Hong Kong SAR China, Hungary, India, Israel, Italy, Latvia, Lithuania, Malaysia, Mexico, Netherlands, Panama, Peru, Philippines, Poland, Portugal, Romania, Russia, Singapore, Slovakia, South Africa, South Korea, Spain, Sweden, Taiwan, Thailand, Türkiye, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02226120. Allocation not applicable; no masking; primary purpose treatment. Start 2014-10-16 (actual); primary completion 2017-12-28 (actual). Results posted on 2019-02-20.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction
- Condition
- Chronic Heart Failure With Reduced Ejection Fraction
- Intervention (Drug)
- LCZ696
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct02226120- Content hash
2b909df94d957e445122062f6d1fe99b692b1fe85a0ad1c27194e1237f564177